
Youngjoo Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7266892/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longâ€term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, realâ€world data (KCSG LU20â€11). Cancer, 2022, 128, 778-787.	4.1	23
2	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2022, 17, 558-567.	1.1	43
3	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Cancers, 2022, 14, 1512.	3.7	1
4	A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute. Cancers, 2022, 14, 2033.	3.7	2
5	A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 213-222.	2.5	8
6	Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer, 2021, 151, 8-15.	2.0	23
7	Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases. Cancers, 2021, 13, 2227.	3.7	3
8	Photon Versus Proton Beam Therapy for T1–3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis. Frontiers in Oncology, 2021, 11, 699172.	2.8	6
9	Oneâ€Step Polymerase Chain Reactionâ€Free Nanowireâ€Based Plasma Cellâ€Free DNA Assay to Detect EML4 â€ Fusion and to Monitor Resistance in Lung Cancer. Oncologist, 2021, 26, e1683-e1692.	E•ALK 3.7	2
10	Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. Cancer Research and Treatment, 2021, 53, 77-86.	3.0	8
11	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer. Cancer Research and Treatment, 2021, 53, 87-92.	3.0	0
12	Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis. Targeted Oncology, 2020, 15, 513-522.	3.6	2
13	The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma. Lung Cancer, 2019, 136, 15-22.	2.0	6
14	De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer. Lung Cancer, 2017, 110, 53-55.	2.0	6
15	Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 77-84.	2.6	8
16	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment, 2017, 49, 1001-1011.	3.0	43
17	The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of <i>EGFR</i> T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating <i>EGFR</i> mutation. Oncotarget, 2016, 7, 43315-43323.	1.8	6
18	Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer. Clinical Lung Cancer, 2015, 16, 46-50.	2.6	26

Youngjoo Lee

#	Article	IF	CITATIONS
19	Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with <i>EGFR</i> -Mutant Lung Cancer. Tuberculosis and Respiratory Diseases, 2014, 77, 271.	1.8	1
20	Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer, 2014, 120, 2090-2098.	4.1	57
21	Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug. Clinical Lung Cancer, 2014, 15, 145-151.	2.6	19
22	Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. Journal of Neuro-Oncology, 2013, 115, 95-101.	2.9	30
23	Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2009-2016.	2.5	74